‘Me Too’ or Breakthrough? Exploring the Oncology Cell Therapy Pipeline

Posted by Katie Blodgett on Jun 26, 2019 8:00:00 AM

Last year, the American Society of Clinical Oncology (ASCO) designated adoptive cell immunotherapy the 2018 clinical cancer “advance of the year” following the 2017 FDA approvals of Kymriah (Novartis) and Yescarta (Kite, a Gilead company). In the year since, we have seen some incremental, notable approvals in the cell and gene therapy space, but we have yet to see additional cell therapy approvals in oncology. However, like a duck sailing smoothly across the water, the relative inactivity above the surface conceals a flurry of development activity taking place below the surface in the oncology pipeline.


>
Read More

How to Pay for Transformative Cell and Gene Therapies

Posted by Bernadette Bourjolly on Oct 13, 2017 8:00:00 AM

Malik Kaman co-wrote this blog post with Bernadette Bourjolly. 

After two decades of failures and setbacks, it’s an exciting time in the field of cell and gene therapies as we witness pioneering advances in a wide range of indications in areas including blood cancers, immunodeficiency and ophthalmology. While cell and gene therapies represent a potential paradigm shift for the treatment of cancer and rare genetic disorders, funding and reimbursement of these unconventional therapies pose major challenges. 


>
Read More